ข่าวประชาสัมพันธ์ Press Releases ข่าวย้อนหลัง หัวข้อข่าว บลอก

วันพุธที่ ๒๐ กันยายน พ.ศ. ๒๕๖๐ ๒๐:๐๔ น.

Food and Healthcare Press Releases

แพคเกจตรวจสุขภาพหัวใจ Know your heart Heathcare—๑๕ ก.ย. ๖๐

โรงพยาบาลหัวใจกรุงเทพ ขอเชิญชวนคุณๆ ร่วมดูแลหัวใจในวันหัวใจโลก World Heart Day 2017 ด้วย "แพคเกจตรวจสุขภาพหัวใจ Know your heart" อาทิ Superior Heart Screening ราคา 7,900 บาท Executive Heart Screening ราคา 30,000 บาท และ Aneurysm Screening

Institut Marques presents their studies on music and the beginning of life at the Massachusetts Institute of Technology Heathcare—๑๙ ก.ย. ๖๐

BOSTON--19 Sep--PRNewswire/InfoQuest
Institut Marques presented at the   Massachusetts Institute of Technology (MIT) its scientific studies on the influence of music on embryonic and fetal development .

Their work , published in the prestigious scientific magazine Ultrasound , has discovered how fetal hearing works, showing that fetuses hear from week 16 (when they measure 11 cm / 4 inches), as long as the sound comes to them from the mother's vagina.

Dr. Marisa Lopez-Teijon, director of Institut Marques, Dr. Alex Garcia-Faura, scientific director of the center, and Lluis Pallares, creator of the Babypod vaginal device, explained the conclusions of the study at MIT. Dr. Alberto Prats, Professor of Anatomy and Human Embryology of the Faculty of Medicine of the University of Barcelona, is also part of the research team.

This session at the Massachusetts Institute of Technology is part of the Ig Nob

Asate AG: Great Honor for Swiss Therapist in America as Snoring and Sleep Apnoea Researcher Alex Heathcare—๑๘ ก.ย. ๖๐

For millions of suffering people, a dream has finally come true: to be able to sleep without snoring. The unconventional innovation of successful Swiss Therapist, Alex Suarez (50), has solved the problem once and for all, and out of 9,000 nominations it

Tetracore(R) Inc. Announces European Approval of the T-COR 8(TM) Portable Real-time PCR Heathcare—๑๘ ก.ย. ๖๐

- The next generation molecular diagnostics platform introduces novel connectivity solution designed to bring testing closer to the patient Tetracore today announced that the T-COR 8 portable real-time PCR thermocycler has achieved CE-IVD status under

Merck Announces Recipients of the Grant for Growth Innovation 2017 Heathcare—๑๘ ก.ย. ๖๐

- The presentation of the grants coincides with the 10th International Meeting of Pediatric Endocrinology - The awards program supports advancements in the field of growth and growth disorders Merck, a leading science and technology company today

Galderma: #Clear# (IGA 0) Rosacea Patients Experience a Delayed Time to Heathcare—๑๘ ก.ย. ๖๐

Today, the results of a pooled analysis of four Galderma-sponsored studies evaluating the use of topical therapies for the treatment of inflammatory papules and pustules of rosacea were presented at the 26th European Academy of Dermatology and

Generation Change 4.0 at Ottobock Heathcare—๑๘ ก.ย. ๖๐

Prof. Hans Georg Nader's youngest daughter, Georgia, will in future be representing the family on Ottobock's supervisory board, which is currently being formed. Otto Bock HealthCare GmbH, based in the German state of Lower Saxony, is undergoing the

Tresiba(R) Trial Shows that People with Type 2 Diabetes who Avoid Severe Hypoglycaemia have a Heathcare—๑๕ ก.ย. ๖๐

Novo Nordisk today announced new analyses from the multinational, double-blinded DEVOTE trial showing that people with type 2 diabetes who experience severe hypoglycaemia (low blood sugar levels) are at greater risk of death. The risk was four-fold

Ascensia Diabetes Care Launches Global Innovation Competition to Find Digital Solutions to Help Heathcare—๑๔ ก.ย. ๖๐

Today, during the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD), Ascensia Diabetes Care announced the launch of the Ascensia Diabetes Challenge, a global innovation competition that is seeking innovative digital

Xultophy(R) Reduces Cardiovascular Risk Factors in People with Type 2 Heathcare—๑๔ ก.ย. ๖๐

In people with type 2 diabetes, Xultophy(R) (insulin degludec/liraglutide) significantly reduced a number of risk factors associated with an increased risk of cardiovascular disease (CVD), compared to basal insulin.[1] According to a new post-hoc

Regen Lab(R) Presents the Latest Clinical Data on the Use of Cellular Matrix(R) Technology in Heathcare—๑๓ ก.ย. ๖๐

The Journal of American Academy of Dermatology, recently issued "the Efficacy of Autologous platelet-rich plasma combined with hyaluronic acid on skin facial rejuvenation: A prospective study" by Hersant B, SidAhmed-Mezi M, Niddam J, La Padula S, Noel W,

Fiasp(R) Significantly Improved Overall Blood Sugar Control in Type 1 Diabetes Heathcare—๑๒ ก.ย. ๖๐

Fiasp(R) (fast-acting insulin aspart), the only approved, new-generation, ultra-fast acting[1]-[3] mealtime insulin, improved overall blood sugar (HbA1c) and post-meal sugar (postprandial glucose or PPG) control over 52 weeks, compared to conventional

More People Treated With Once-weekly Semaglutide Achieved Reductions in Both Glucose and Weight vs. Heathcare—๑๒ ก.ย. ๖๐

A post-hoc analysis of the SUSTAIN 1-5 trials demonstrated that a greater proportion of adults with type 2 diabetes achieved a clinically meaningful reduction in both HbA1c and body weight with once-weekly semaglutide vs. comparator treatments.

Unleashing the Power of the Latest Pharmaceutical Research for Simplified Global Healthcare Heathcare—๑๒ ก.ย. ๖๐

Associated with over 1000 scientific societies and organizations, Conference Series is scheduled to organize pharmaceutical conferences in Europe, USA, and Asia Pacific with a view to unleash precious scientific findings for the benefit of

Merck Set to Join Forces with Project Data Sphere to Pioneer Global Oncology Big Data Heathcare—๑๒ ก.ย. ๖๐

- Big data platform to help accelerate innovative discovery, development and delivery of new approaches in cancer care - Enhanced analytical capabilities to better define personalized treatment options and help predict treatment outcomes - Focused on

Galderma: Combined Use of Rosacea Therapies Ivermectin 1% Cream and Brimonidine 0.33% Gel Evaluated Heathcare—๑๑ ก.ย. ๖๐

Today, the results of a study evaluating the combined use of topical rosacea treatments ivermectin 1% cream and brimonidine 0.33% gel were published in the Journal of Drugs in Dermatology. (Logo: http://mma.prnewswire.com/media/554005/Galderma_Logo.jpg

Janssen to Discontinue Hepatitis C Development Program Heathcare—๑๑ ก.ย. ๖๐

- Viral Hepatitis Research and Development to Focus on Addressing Significant Unmet Needs in Chronic Hepatitis B Janssen Sciences Ireland UC (Janssen), today announced a strategic decision to discontinue further development of the investigational

Merck #Grant for Oncology Innovation Awards Recognize Recipients for Pushing Boundaries in Oncology Heathcare—๑๑ ก.ย. ๖๐

- EUR1 million grant funded by Merck supports research with the potential to advance implementation of personalized treatment for solid tumors - Three winners selected from 100 scientifically diverse applicants worldwide Merck, a leading science and

Borderless Access Launches #HealthSight# - A Programmatic Sampling Suite for Healthcare Heathcare—๗ ก.ย. ๖๐

Borderless Access, a global digital MR solutions company enters into healthcare research with the launch of its new product offering 'HealthSight', in line with its vision to be the global leader in providing digital market research solutions for

Medical Devices ASEAN 2018 all set to launch Thailand as the emerging hub of medical and healthcare Heathcare—๑ ก.ย. ๖๐

Medical Devices ASEAN (MDA) 2018, the international exhibition and congress on medical devices, technologies, services and general healthcare, all set to feature more than 100 international companies exhibiting a full range of cutting-edge medical

Merck Opens its First Customer Food Safety Studio Heathcare—๓๑ ส.ค. ๖๐

- New Food Safety Studio in Bellevue, Washington, serves as global center for innovation and collaboration - Demonstration and training lab space extends product and process development to customers Merck , a leading science and technology company, has

Merck KGaA, Darmstadt, Germany: Driving Innovation in Cancer Care at ESMO 2017 With New Data in Heathcare—๓๑ ส.ค. ๖๐

-Data to showcase Merck KGaA, Darmstadt, Germany's strong and diverse pipeline ranging from immuno-oncology to DNA damage response - Avelumab data validate potential in hard-to-treat cancers and highlight progress of the JAVELIN clinical development

Merck: Driving Innovation in Cancer Care at ESMO 2017 With New Data in Hard-to-Treat Heathcare—๓๑ ส.ค. ๖๐

Erbitux(R): 576P, 593P, 1068P, 1579P; avelumab: 1227P, 913P, 1377TiP, 882P, 856P; M6620 (ATR inhibitor): 242PD; M2698 (dual p70S6K/Akt inhibitor): 370PD, 393P; tepotinib (c-Met kinase inhibitor): 701P -Data to showcase Merck's strong and diverse

Merck Collaborates with Angiex to Speed Clinical Readiness of New Cancer Heathcare—๓๐ ส.ค. ๖๐

Merck , a leading science and technology company, today announced a new collaboration with Angiex, Inc., Cambridge, Massachusetts, USA to support the biotechnology start-up's ability to speed its lead oncology antibody drug candidate to clinical use.